Phase I study results of APG-115, a MDM2-p53 antagonist in Chinese patients with advanced liposarcoma and other solid tumors.
Xing Zhang(Sun Yat-sen University), Yifan Zhai(Unknown), Dajun Yang, Wenqin Liu, Ruiqing Peng(Sun Yat-sen University), Zhiyan Liang(East China University of Science and Technology), Qiuzhong Pan(Sun Yat-sen University), Shulan He(Ningxia Medical University), Shan Zeng(Central South University), Yang Zhang(Guangdong Testing Institute for Product Quality Supervision), Li Zhang(Jinan Stomatological Hospital), Xizhi Wen(Sun Yat-sen University), Yuxiang Ma(Sun Yat-sen University), Desheng Weng(Sun Yat-sen University), Hengbang Wang, Lichuang Men, Guojuan Chen
Cited by 7
Related Papers
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
|Journal of Thoracic Oncology|2015|682
LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response
|The Journal of Immunology|2000|402